Peripartum glucose control - how, why, who? — ASN Events
  1. Schedule
  2. Session 5: Peripartum and Neonatal
  3. Peripartum glucose control - how, why, who?

Peripartum glucose control - how, why, who? (#25)

Christopher Rowe 1
  1. John Hunter Hospital, Newcastle, NSW, Australia

Is achieving glycaemic targets in the hours preceding labour and birth important to reduce maternal and neonatal risks, or is this less important than weeks of at-target antenatal glucose control?  Are there particular subgroups in whom glycaemic control is particularly important?  What the evidence to support specific glucose targets in the peripartum, and how should these safely be achieved?  This session will review available evidence and management guidelines, and present the experience of the Pregnancy-IVI to maintain normoglycaemia in labour, and where birth has occurred shortly after antenatal corticosteroids .  

  1. Rowe CW, Qiao V, Ramesh S, Rosee P, Sathiakumar A, McWhae-Brown S, et al., 'Adoption of a pregnancy-specific intravenous insulin protocol (Pregnancy-IVI) at a regional centre has equivalent safety and efficacy outcomes as a tertiary hospital', Diabetic Medicine, 40 (2023)
  2. Rowe CW, Putt E, Brentnall O, Gebuehr A, Allabyrne J, Woods A, Wynne K, 'An intravenous insulin protocol designed for pregnancy reduces neonatal hypoglycaemia following betamethasone administration in women with gestational diabetes', Diabetic Medicine, 36 228-236 (2019)
  3. Rowe CW, Watkins B, Brown K, Delbridge M, Addley J, Woods A, Wynne K, 'Efficacy and safety of the pregnancy-IVI, an intravenous insulin protocol for pregnancy, following antenatal betamethasone in type 1 and type 2 diabetes', Diabetic Medicine, 38 (2021)
#ADIPS_ASM2023